Headquartered in Boston MA with additional operations in Sudzow, China, Silicon Therapeutics (SiTX) is a physics-driven, drug discovery company structured around small molecule cancer therapeutics targeting innate immunity to light the spark within immunologically cold tumors. In late February 2021, it was announced that Silicon Thereapeutics had been acquired by Roivant Sciences (NASDA:ROIV) - a biopharmaceutical firm focused on completing the development of promising late-stage drug candidates - in a $450M transaction. Designed particularly to support high throughput drug discovery and design, the unique computational physics-based platform of Silicon Therapeutics can accurately simulate the physical motion and properties of biological targets at atomistic resolution to reveal unique insights into the drug design process. Cohesively integrated with a world-class wet lab including biophysics, chemistry, and biology, the firm's platform enables rapid hypothesis-driven data generation to advance drug discovery projects on targets that have traditionally been thought of as "undruggable". The SiTX lead program is a small molecule STING agonist for systemic delivery in I/O that is slated to enter the clinic in mid-2020.
